JPWO2020247871A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020247871A5
JPWO2020247871A5 JP2021572583A JP2021572583A JPWO2020247871A5 JP WO2020247871 A5 JPWO2020247871 A5 JP WO2020247871A5 JP 2021572583 A JP2021572583 A JP 2021572583A JP 2021572583 A JP2021572583 A JP 2021572583A JP WO2020247871 A5 JPWO2020247871 A5 JP WO2020247871A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
acid sequence
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021572583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535924A5 (https=
JP2022535924A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036493 external-priority patent/WO2020247871A2/en
Publication of JP2022535924A publication Critical patent/JP2022535924A/ja
Publication of JP2022535924A5 publication Critical patent/JP2022535924A5/ja
Publication of JPWO2020247871A5 publication Critical patent/JPWO2020247871A5/ja
Priority to JP2025050785A priority Critical patent/JP2025111446A/ja
Pending legal-status Critical Current

Links

JP2021572583A 2019-06-06 2020-06-05 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 Pending JP2022535924A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050785A JP2025111446A (ja) 2019-06-06 2025-03-25 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962858254P 2019-06-06 2019-06-06
US62/858,254 2019-06-06
US202062978662P 2020-02-19 2020-02-19
US62/978,662 2020-02-19
PCT/US2020/036493 WO2020247871A2 (en) 2019-06-06 2020-06-05 Compositions and methods relating to tumor activated t cell engagers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050785A Division JP2025111446A (ja) 2019-06-06 2025-03-25 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法

Publications (3)

Publication Number Publication Date
JP2022535924A JP2022535924A (ja) 2022-08-10
JP2022535924A5 JP2022535924A5 (https=) 2023-06-09
JPWO2020247871A5 true JPWO2020247871A5 (https=) 2023-06-09

Family

ID=73652312

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021572583A Pending JP2022535924A (ja) 2019-06-06 2020-06-05 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法
JP2025050785A Pending JP2025111446A (ja) 2019-06-06 2025-03-25 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050785A Pending JP2025111446A (ja) 2019-06-06 2025-03-25 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法

Country Status (6)

Country Link
US (3) US20230220105A1 (https=)
EP (1) EP3980131A4 (https=)
JP (2) JP2022535924A (https=)
KR (1) KR20220052898A (https=)
CN (1) CN114423499A (https=)
WO (2) WO2020247871A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200385440A1 (en) * 2017-12-07 2020-12-10 Janux Therapeutics, Inc. Modified bispecific t cell receptors
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
JP2024518539A (ja) * 2020-04-04 2024-05-01 ジャナックス セラピューティクス，インク． 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
WO2022035866A1 (en) 2020-08-11 2022-02-17 Janux Therapeutics, Inc. Cleavable linker compositions and methods
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
EP4337794A4 (en) * 2021-05-11 2025-07-02 Janux Therapeutics Inc ANTIBODIES TARGETING EGFR AND CD3 AND THEIR USES
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
EP4519326A1 (en) * 2022-05-04 2025-03-12 Janux Therapeutics, Inc. Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
KR20250051722A (ko) * 2022-08-18 2025-04-17 이뮤노코어 리미티드 멀티-도메인 결합 분자
CN121443645A (zh) * 2023-05-03 2026-01-30 佳努克斯治疗公司 靶向cd3的肿瘤活化的抗体及其用途
WO2025085855A2 (en) * 2023-10-20 2025-04-24 BioNTech SE Multispecific t cell engagers compositions and methods of use thereof
WO2025085862A2 (en) * 2023-10-20 2025-04-24 BioNTech SE Multispecific t cell engagers compositions and methods of use thereof
GB2641580A (en) * 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031264A1 (en) * 1996-01-25 2001-10-18 Andrew Segal Vaccine compositions and methods of modulating immune responses
BRPI0713421A2 (pt) * 2006-06-14 2012-03-13 Imclone Systems Incorporated Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
RS53008B2 (sr) * 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
US20110214199A1 (en) * 2007-06-06 2011-09-01 Monsanto Technology Llc Genes and uses for plant enhancement
AU2008328726B2 (en) * 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
WO2013041865A1 (en) * 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
CN104540518A (zh) * 2012-04-27 2015-04-22 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
CN104271602B (zh) * 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
IL270562B (en) * 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
JP7020909B2 (ja) * 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2016210447A1 (en) * 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
JP7038353B2 (ja) * 2016-04-13 2022-03-18 ヴィヴィア バイオテック，エス．エル エクスビボのｂｉｔｅ活性化ｔ細胞
JP7101621B2 (ja) * 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
CA3287794A1 (en) * 2017-10-14 2025-10-27 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
KR20210020903A (ko) * 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티

Similar Documents

Publication Publication Date Title
JPWO2020247871A5 (https=)
CN107922486B (zh) 异源二聚体多特异性抗体形式
Kriangkum et al. Bispecific and bifunctional single chain recombinant antibodies
ES2764111T3 (es) Anticuerpos multiespecíficos
RU2015144098A (ru) Четырехвалентные биспецифические антитела
JP2021159081A5 (https=)
JP7600328B2 (ja) ＰＤ－１とＴＧＦ－ｂｅｔａを標的とした四価二重特異性抗体、その製造方法および用途
JP2021510521A5 (https=)
JP2023123649A5 (https=)
JPWO2020011964A5 (https=)
JP2022009816A5 (https=)
JP2025124718A5 (https=)
FI3765525T3 (fi) Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä
JP2026004299A5 (https=)
CN116964084A (zh) 双特异性抗体
JP2015520172A5 (https=)
JPWO2021184673A5 (https=)
JPWO2022094299A5 (https=)
JPWO2020011972A5 (https=)
JPWO2023034922A5 (https=)
JPWO2021139758A5 (https=)
JPWO2020048525A5 (https=)
JPWO2019147670A5 (https=)
WO2024061224A1 (zh) 抗her2抗体及其用途
JPWO2023141611A5 (https=)